VaxInnate Begins Phase I Clinical Trial to Evaluate Quadrivalent Vaccine for Prevention of Seasonal Flu

March 19, 2014 VaxInnate Corporation┬átoday announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. VaxInnate is a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines. The VAX2012Q clinical trial is being funded in whole with federal funds from …